Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Sektion für Stammzell- und Immuntherapie > Publikationen / Publications > 2015 - 2018

Publikationen / Publications

2018

New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW. Br J Haematol. 2018; 180(6):808-820.(PubMed)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P. Haematologica 2018; 103(2):197-211. (PubMed)

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N. Haematologica 2018; 103(2):237-245. (PubMed)

2017

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries. Klausz K, Cieker M, Kellner C, Oberg HH, Kabelitz D, Valerius T, Burger R, Gramatzki M, Peipp M. Oncotarget. 2017; 8(44):77552-77566. (PubMed)

An Fc double-engineered CD20 antibody with enhanced ability to trigger complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. Wirt T, Roßkopf S, Rösner T, Eichholz KM, Kahrs A, Lutz S, Kretschmer A, Valerius T, Klausz K, Otte A, Gramatzki M, Peipp M, Kellner C. Transfus Med Hemother. 2017; 44(5):292-300. (PubMed)

Modulating cytotoxic effector functions by Fc engineering to improve cancer therapy. Kellner C, Otte A, Cappuzzello E, Klausz K, Peipp M.Transfus Med Hemother. 2017; 44(5):327-336. (PubMed)

Antibody engineering – tailor-made next generation antibodies by molecular design. Humpe A, Peipp M. Transfus Med Hemother. 2017; 44(5):290-291. (PubMed)

Antibody isotypes for tumor immunotherapy. Kretschmer A, Schwanbeck R, Valerius T, Rösner T. Transfus Med Hemother. 2017; 44:320-326. (PubMed)

Monoclonal antibodies against epidermal growth factor receptor acquire an ability to kill tumor cells through complement activation by mutations that selectively facilitate the hexamerization of IgG on opsonized cells.Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PW, Valerius T. J Immunol. 2017;198(4):1585-1594. (PubMed)

STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer. Binder S, Hösler N, Riedel D, Zipfel I, Buschmann T, Kämpf C, Reiche K, Burger R, Gramatzki M, Hackermüller J, Stadler PF, Horn F. Sci Rep. 2017;7:7976. (PubMed)

CD20-specific immunoligands engaging NKG2D enhance γδ T cell-mediated lysis of lymphoma cells. Peipp M, Wesch D, Oberg HH, Lutz S, Muskulus A, van de Winkel JGJ, Parren PWHI, Burger R, Humpe A, Kabelitz D, Gramatzki M, Kellner C. Scand J Immunol. 2017; 86(4):196-206. (PubMed)

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts. Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C. Blood. 2017; 130(13):1543-1552. (PubMed)

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T. Br J Haematol. 2017 Apr 27. (PubMed)

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A. J Hematol Oncol. 2017;10(1):130. (PubMed)

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma. Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC. Leukemia. 2017; 31(8):1816-1819. (PubMed)

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG. Br J Haematol. 2017; 179(1):66-74. (PubMed)

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.Fürst D, Niederwieser D, Bunjes D, Wagner EM, Gramatzki M, Wulf G, Müller CR, Neuchel C, Tsamadou C, Schrezenmeier H, Mytilineos J. Haematologica. 2017;102(4):796-803. (PubMed)

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and MarrowTransplantation. Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland SO, KrögerN. Bone Marrow Transplant. 2017;52(4):552-560. (PubMed)

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C. Leukemia. 2017;31(6):1463-1466. (PubMed)

Dental status does not predict infection during stem cell transplantation: a single-center survey. Guenther A, Losch E, Schiessl M, Schrauder A, Humpe A, Repp R, Nitsche T, Wiltfang J, Gramatzki M. Bone Marrow Transplant. 2017; 52(7):1041-1043. (PubMed)

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland SO, Kröger N; CLL subcommittee, Chronic Malignancies Working Party. Br J Haematol. 2017; 178(4):521-533. (PubMed)

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J. Bone Marrow Transplant. 2017;52(3):372-380. (PubMed)

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S. Brit J Haematol 2017; 179(4):586-597.(PubMed)

Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients.Tsamadou C, Fürst D, Vucinic V, Bunjes D, Neuchel C, Mytilineos D, Gramatzki M, Arnold R, Wagner EM, Einsele H, Müller C, Schrezenmeier H, Mytilineos J. Haematologica 2017; 102(11):1947-1955.

(PubMed)

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen NS, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig J; CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Clinical Lymphoma, Myeloma & Leukemia 2017; 17(10):667-675.(PubMed)

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Burger R, Guenther A, Klausz K, Staudinger M, Peipp M, Murga Penas EM, Rose-John S, Wijdenes J, Gramatzki M. Haematologica 2017;102(2):381-390. (PubMed)

 

2016

 

Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell
transplantation. Fuerst D, Neuchel C, Niederwieser D, Bunjes D, Gramatzki M, Wagner E, Wulf G, Glass B, Pfreundschuh M, Einsele H, Arnold R, Stuhler G, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Wattad M, Hertenstein B, Klein S, Ringhoffer M, Mytilineos D, Tsamadou C, Mueller C, Schrezenmeier H, Mytilineos J.  Blood 2016;128(26):3169-3176. (PubMed)

Panobinostat plus bortezomib and dexmethasone in previously treated multiple myeloma: outcomes by prior treatment. Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Blood. 2016;127(6):713-21. (PubMed)

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T. Cancer Res. 2016;76(2):403-17. (PubMed)                

Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells. Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ. J Immunol. 2016;197(12):4829-4837. (PubMed)

Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?Engelhardt M, Ihorst G, Caers Jo, Günther A, Wäsch R. Haematologica. 2016;101(11):1276-1278. (PubMed

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf HH, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H.Haematologica. 2016;101(11):1398-1406. (PubMed            

2015

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M. Oncoimmunology. (2015) (PubMed)

Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial. Delforge M, Devos T, Rowe J, Español I, Durrant ST, Raddoux J, Boogaerts M, Gramatzki M, Gunther A. Leuk Lymphoma. (2015) (PubMed)

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Br J Haematol. (2015) 168(6): 824-34 (PubMed)

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Günther A, Baumann P, Burger R, Kellner C, Klapper W, Schmidmaier R, Gramatzki M. Haematologica. (2015) 100(4): 541-7 (PubMed)

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, Gramatzki M, Kellner C.  Oncotarget. (2015) 6(31): 32075-88 (PubMed)

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing. Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.  Cancer Immunol Res. (2015) (PubMed)

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, Boross P, Rouwendal G, Leusen JH. MAbs. (2015) (PubMed)

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. Derer S, Cossham M, Rösner T, Kellner C, Beurskens FJ, Schwanbeck R, Lohse S, Sina C, Peipp M, Valerius T. J Immunol. (2015) 195(10): 5077-87 (PubMed)

The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development. Klausz K, Kellner C, Derer S, Valerius T, Staudinger M, Burger R, Gramatzki M, Peipp M.  J Immunol Methods. (2015) 418: 75-83 (PubMed)